TCM

Which are the latest news on TCM?

Why is TCM Ltd falling/rising?

As of 28-Jun, TCM Ltd's stock price is declining, currently at 44.27, reflecting a significant year-to-date drop of 30.98% and underperformance compared to the benchmark Sensex. The company's poor financial health, including operating losses and a high Debt to EBITDA ratio, further exacerbates negative investor sentiment.

As of 28-Jun, TCM Ltd's stock price is falling, currently at 44.27, reflecting a change of -2.12 (-4.57%). The stock has underperformed its sector by 3.57% today and has experienced a trend reversal, falling after two consecutive days of gains. The stock touched an intraday low of Rs 43, marking a decline of 7.31%. <BR><BR>In terms of performance over various periods, TCM Ltd has seen a significant decline, with a year-to-date drop of 30.98%, while the benchmark Sensex has only decreased by 9.53%. The stock's performance over the past month shows a decrease of 8.31%, contrasting with a slight increase of 0.80% in the Sensex. Additionally, TCM Ltd has been trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend.<BR><BR>The company's financial health is also concerning, as it has reported operating losses and has a high Debt to EBITDA ratio of -4.91 times, suggesting a low ability to service its debt. Recent financial results indicate a significant drop in profit before tax (PBT) and net sales, with PBT falling by 425.71% and net sales declining by 23.28%. Furthermore, the company has recorded a negative EBITDA of Rs. -4.51 cr, which raises concerns about its long-term fundamental strength.<BR><BR>Overall, the combination of poor financial performance, negative investor sentiment, and underperformance relative to the sector contributes to the decline in TCM Ltd's stock price.

How big is TCM?

As of 10th June, TCM Ltd has a market capitalization of 36.00 Cr and reported net sales of 19.74 Cr with a loss of 5.81 Cr over the latest four quarters. The company's shareholder's funds are 30.52 Cr, and total assets amount to 76.40 Cr.

As of 10th June, TCM Ltd has a market capitalization of 36.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, TCM reported net sales of 19.74 Cr. However, the company experienced a loss of 5.81 Cr during the same period.<BR><BR>The latest annual reporting period for TCM shows shareholder's funds of 30.52 Cr and total assets amounting to 76.40 Cr.

Who are in the management team of TCM?

The management team of TCM includes Managing Director Joseph Varghese, Executive Director Ramesh Babu, and Company Secretary Gokul V Shenoy, along with several non-executive and independent directors. This team is responsible for the company's governance and strategic direction.

The management team of TCM includes the following individuals:<BR><BR>1. **Joseph Varghese** - Managing Director<BR>2. **Ramesh Babu** - Executive Director<BR>3. **Gokul V Shenoy** - Company Secretary & Compliance Officer<BR><BR>Additionally, the board features several non-executive and independent directors, including:<BR><BR>- George Varghese - Non-Executive & Non-Independent Director<BR>- Rani Jose - Non-Executive & Non-Independent Director<BR>- Gopalakrishnan Mahesh - Independent Director<BR>- Jose Jacob - Independent Director<BR>- Sreenivasa Bhat - Independent Director<BR>- Bobby John - Independent Director<BR><BR>This team plays a vital role in the governance and strategic direction of the company.

Who are the peers of the TCM?

TCM's peers include Gayatri BioOrga, Ritesh Intl, Shreyas Interm, Camex, Haryana Leather, Venlon Enterprises, Sonal Adhesives, and Advance Petroch. In terms of management risk, growth, and capital structure, TCM ranks below average compared to some peers, with a 1-year return of 10.91%.

Peers: The peers of TCM are Gayatri BioOrga., Ritesh Intl., Shreyas Interm., Camex, Haryana Leather, Venlon Enterpris, Sonal Adhesives, and Advance Petroch.<BR><BR>Quality Snapshot: Excellent management risk is observed at Haryana Leather and Sonal Adhesives, while Average management risk is found at Ritesh Intl. and the rest. Below Average management risk is noted at Shreyas Interm., Camex, TCM, Venlon Enterpris, and Advance Petroch. In terms of Growth, Good growth is seen at Sonal Adhesives, Average growth is found at Ritesh Intl., Shreyas Interm., Venlon Enterpris, and the rest, while Below Average growth is noted at Gayatri BioOrga., TCM, Camex, Haryana Leather, and Advance Petroch. For Capital Structure, Good capital structure is observed at Camex and Haryana Leather, Average capital structure is found at Ritesh Intl., Sonal Adhesives, and Advance Petroch, while Below Average capital structure is noted at Gayatri BioOrga., Shreyas Interm., TCM, and Venlon Enterpris.<BR><BR>Return Snapshot: Ritesh Intl. has the highest 1-year return at 24.60%, while Shreyas Interm. has the lowest at -35.93%. TCM's own 1-year return is 10.91%, which is higher than Shreyas Interm. but lower than Ritesh Intl. Additionally, the six-month returns are negative for Gayatri BioOrga., Shreyas Interm., Venlon Enterpris, and TCM.

What does TCM do?

TCM Ltd trades and installs solar panels, manufactures cattle feed, and operates in the Commodity Chemicals industry. As of March 2026, it reported net sales of 5 Cr and a net loss of 2 Cr, with a market cap of INR 36 Cr.

Overview: <BR>TCM Ltd is engaged in the trading and installation of solar panels, manufacturing of cattle feed, and operates within the Commodity Chemicals industry as a micro-cap company.<BR><BR>History: <BR>TCM Ltd was initially incorporated as 'Travancore Chemical & Mfg. Co. Ltd' in April 1943. The company underwent a name change to TCM Limited, with a new Certificate of Incorporation issued on 10 September 1996. The latest reported quarterly results indicate net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 5 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: -2 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 36 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 29 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.87 <BR>Return on Equity: -23.52% <BR>Price to Book: 1.45<BR><BR>Contact Details: <BR>Address: 28/2917 Aiswarya Shanthi Nagar, Ponneth Temple Road Cochin Kerala : 682020 <BR>Tel: 91-0484-2316771 <BR>Email: info@tcmlimited.in <BR>Website: http://www.tcmlimited.in

Should I buy, sell or hold TCM Ltd?

Are TCM Ltd latest results good or bad?

TCM Ltd's latest results are concerning, showing a net loss of ₹1.65 crore and a 35.69% drop in revenue year-over-year, indicating significant operational distress and ongoing challenges in maintaining profitability. Overall, the financial performance suggests a critical need for management to address these issues.

TCM Ltd's latest results are concerning and indicate significant operational distress. In the fourth quarter of FY26, the company reported a net loss of ₹1.65 crore, which is a staggering 140.94% decline year-over-year. Revenue also fell sharply by 35.69% compared to the same quarter last year, coming in at ₹4.92 crore. This marks a continued trend of declining sales, as the company has faced negative operating margins for six consecutive quarters, with the latest operating margin at -23.78%.<BR><BR>The financial performance highlights a company struggling to maintain profitability, with cash flow challenges compounding the issues. The return on equity is a mere 0.55%, and the overall financial health appears weak, with a deteriorating balance sheet and no positive cash flow from operations.<BR><BR>While the stock did see a short-term bounce, closing up 4.93% recently, the underlying fundamentals suggest that the company's operational challenges are structural rather than temporary. Given these factors, the latest results can be classified as bad, reflecting a critical need for management to address these ongoing issues to restore viability and investor confidence.

When is the next results date for TCM Ltd?

The next results date for TCM Ltd is 26 May 2026.

The next results date for TCM Ltd is scheduled for 26 May 2026.

How has been the historical performance of TCM?

TCM's historical performance shows significant fluctuations, with net sales peaking at 32.23 Cr in March 2024 before declining to 26.01 Cr in March 2025. However, the company reported a recovery in profitability, achieving a profit after tax of 1.40 Cr in March 2025, up from a loss of 2.29 Cr the previous year.

Answer:<BR>The historical performance of TCM shows significant fluctuations in its financial metrics over the years, with a notable recovery in recent periods.<BR><BR>Breakdown:<BR>TCM's net sales peaked at 32.23 Cr in March 2024 but fell to 26.01 Cr in March 2025, following a substantial increase from just 7.35 Cr in March 2023. The total operating income mirrored this trend, reaching 32.23 Cr in March 2024 before declining to 26.01 Cr in March 2025. The company's total expenditure, excluding depreciation, was 28.17 Cr in March 2025, down from 34.47 Cr in March 2024, indicating a reduction in costs. Despite this, TCM reported an operating profit (PBDIT) of 2.31 Cr in March 2025, a recovery from a loss of 1.81 Cr in March 2024. The profit before tax also improved to 1.37 Cr in March 2025, compared to a loss of 2.25 Cr in the previous year. Consequently, the profit after tax turned positive at 1.40 Cr in March 2025, reversing a loss of 2.29 Cr in March 2024. The consolidated net profit for March 2025 was 1.61 Cr, a significant improvement from the loss of 1.95 Cr in March 2024. TCM's total assets decreased to 76.40 Cr in March 2025 from 83.79 Cr in March 2024, while total liabilities also fell to 76.40 Cr from 83.79 Cr, indicating a stabilization in the company's financial position. The cash flow from operating activities was negative at -10.00 Cr in March 2025, although cash flow from financing activities showed a positive inflow of 10.00 Cr. Overall, TCM's financial performance reflects a recovery trajectory, with improvements in profitability metrics despite challenges in sales and cash flow.

Who are the top shareholders of the TCM?

The top shareholder of TCM is Joseph Varghese, holding 49.48%, with no pledged promoter holdings. The highest public shareholder is Lici Asm Non Par at 7.41%, while individual investors collectively own 38.8% of the shares.

The top shareholders of TCM include the promoters, with Joseph Varghese holding the largest share at 49.48%. There are no pledged promoter holdings, and mutual funds and foreign institutional investors currently do not hold any shares in the company. The highest public shareholder is Lici Asm Non Par, who owns 7.41%. Additionally, individual investors collectively hold 38.8% of the shares.

Is TCM overvalued or undervalued?

As of April 25, 2023, TCM is considered risky and overvalued with a PE Ratio of 18.69 and an EV to EBITDA of -19.11, significantly underperforming compared to peers like UPL and BASF India, and has a year-to-date return of -14.82% versus the Sensex's 5.59%.

As of 25 April 2023, TCM's valuation grade has moved from does not qualify to risky, indicating a shift in its perceived investment quality. The company is currently assessed as overvalued given its financial ratios and performance metrics. Key ratios include a PE Ratio of 18.69, an EV to EBITDA of -19.11, and a ROE of 5.31%. <BR><BR>In comparison to peers, TCM's valuation stands out unfavorably; for instance, UPL, which is rated as attractive, has a PE Ratio of 38.74 and an EV to EBITDA of 8.35. Similarly, BASF India, also attractive, shows a PE Ratio of 45.64 and an EV to EBITDA of 28.4. Furthermore, TCM's recent stock performance has lagged behind the Sensex, particularly in the year-to-date return of -14.82% compared to the Sensex's 5.59%, reinforcing the notion that TCM is overvalued in the current market context.

What is the technical trend for TCM?

As of June 5, 2025, TCM's technical trend has shifted to a bearish stance with moderate strength, driven by bearish signals from moving averages and Bollinger Bands, despite some mixed momentum indicators.

As of 5 June 2025, the technical trend for TCM has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. Key indicators driving this assessment include the bearish signals from the daily moving averages and the Bollinger Bands on both weekly and monthly time frames. The MACD shows a mildly bullish signal on the weekly but is bearish on the monthly, indicating mixed momentum. The KST is mildly bullish weekly but bearish monthly, further contributing to the overall bearish outlook. The Dow Theory indicates a mildly bullish stance on the weekly but no trend on the monthly, suggesting uncertainty in the longer term. Overall, the bearish trend is supported by the prevailing indicators despite some mixed signals.

Has TCM declared dividend?

No Dividend History Available